Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shawn, Zinnen"'
Publikováno v:
Bone Reports, Vol 9, Iss , Pp 47-60 (2018)
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bo
Externí odkaz:
https://doaj.org/article/22c276b4b5674c1284daf05148ff0c7b
Publikováno v:
Bioconjug Chem
Patients with cancer-induced bone disease, including primary bone cancers such as osteosarcoma (OS) and metastases from other tissues of origin, present a high unmet medical need. We present a potential therapeutic approach built upon a proven bone-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c01dc09fcf2ed474a1e7a5bfbc607a
https://doi.org/10.1021/acs.bioconjchem.1c00507
https://doi.org/10.1021/acs.bioconjchem.1c00507
Autor:
Gareth D Healey, Jennifer A Lockridge, Shawn Zinnen, Julian M Hopkin, Ivan Richards, William Walker
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e90338 (2014)
Developing siRNA therapeutics poses technical challenges including appropriate molecular design and testing in suitable pre-clinical models. We previously detailed sequence-selection and modification strategies for siRNA candidates targeting STAT6. H
Externí odkaz:
https://doaj.org/article/e47efed6893641499d5f6df141f92191
Publikováno v:
Bone Reports
Bone Reports, Vol 9, Iss, Pp 47-60 (2018)
Bone Reports, Vol 9, Iss, Pp 47-60 (2018)
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1610755648de054ddf129c55c6172088
https://doi.org/10.1016/j.bonr.2018.06.007
https://doi.org/10.1016/j.bonr.2018.06.007
Publikováno v:
The Oncologist
Lessons Learned Results are consistent with MBC-11 targeting and treating cancer-induced bone lesions by concentrating cytarabine and etidronate at the site of disease. MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2998634fb4752573406f60ef74f98f
https://doi.org/10.1634/theoncologist.2018-0707
https://doi.org/10.1634/theoncologist.2018-0707
Autor:
Harri Lönnberg, Luis Sanchez-Perez, Vivian Negron, David P Sebesta, Shawn Zinnen, Monica M. Reinholz, Diane F. Jelinek, Anthony J. Croatt, Amylou C. Dueck, Leslie M. Jonart, Henry B F Hal Dixon, James N. Ingle, Wilma L. Lingle, Thomas C. Spelsberg, Toshiyuki Yoneda, Gregory G. Reinholz, David Dingli, Kathleen A Kitzmann, Karl A. Nath, Abdalla K Abdalla, Bonnie K. Arendt, Stephen J. Russell, Alexander Karpeisky, Amy K Bruzek
Publikováno v:
Bone. 47:12-22
Despite palliative treatments, tumor-induced bone disease (TIBD) remains highly debilitating for many cancer patients and progression typically results in death within two years. Therefore, more effective therapies with enhanced anti-resorptive and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::551b1530cde98df8044875e1157ad4f0
https://doi.org/10.1016/j.bone.2010.03.006
https://doi.org/10.1016/j.bone.2010.03.006
Autor:
Karl Kossen, Toshiyuki Koya, Erwin W. Gelfand, Barry Polisky, Joseph J. Lucas, Shawn Zinnen, Tricia N. Lively, Ivan Richards, Annette Balhorn, Katsuyuki Takeda
Publikováno v:
The Journal of Allergy and Clinical Immunology
Background RNA interference is an endogenous cellular mechanism in which short interfering RNAs (siRNAs) direct the sequence specific degradation of a target mRNA. siRNAs can be synthesized with chemical modifications to increase stability and reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977240a92dac71c8041fe1b55f14258f
https://doi.org/10.1016/j.jaci.2007.08.029
https://doi.org/10.1016/j.jaci.2007.08.029
Autor:
R Samul, Jingshi Shen, K. Bouhana, Yoshitsugu Saishin, Peter A. Campochiaro, Chandra Vargeese, K Kossen, Kathy Fosnaugh, Hideo Akiyama, Shawn Zinnen, Raquel Lima e Silva, Hongting Liu, Pamela Pavco, Sean F. Hackett, R. Aitchison, A. Gomez
Publikováno v:
Gene Therapy. 13:225-234
In this study, we used small interfering RNA (siRNA) directed against vascular endothelial growth factor receptor 1 (vegfr1) mRNA to investigate the role of VEGFR1 in ocular neovascularization (NV). After evaluating many siRNAs, Sirna-027 was identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af07e76dc3ff62d3bd018ef6c5b54e9b
https://doi.org/10.1038/sj.gt.3302641
https://doi.org/10.1038/sj.gt.3302641
Autor:
Shawn Zinnen, Larisa Plekhova, Alexander Karpeisky, Marina Roudas, Alexander Alexandrov, Eric K. Rowinsky
Publikováno v:
Journal of Clinical Oncology. 35:2589-2589
2589 Background: MBC-11 is a first-in-class therapeutic conjugate of the bone targeting bisphosphonate etidronate covalently linked to the antimetabolite cytosine arabinoside (Ara-C). In preclinical studies, MBC-11 localizes at the site of cancer-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0e6e0d8247719078960387d2eda3d7e
https://doi.org/10.1200/jco.2017.35.15_suppl.2589
https://doi.org/10.1200/jco.2017.35.15_suppl.2589
Autor:
William Walker, Julian M. Hopkin, Jennifer A. Lockridge, Gareth D. Healey, Shawn Zinnen, Ivan Richards
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e90338 (2014)
PLoS ONE
PLoS ONE
Developing siRNA therapeutics poses technical challenges including appropriate molecular design and testing in suitable pre-clinical models. We previously detailed sequence-selection and modification strategies for siRNA candidates targeting STAT6. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cecde221bde224935623bd368fe05623
http://europepmc.org/articles/PMC3937390?pdf=render
http://europepmc.org/articles/PMC3937390?pdf=render